Estados Unidos - inglés - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 250 mg - carefully consider the potential benefits and risks of naproxen, ec-naproxen, anaprox, anaprox ds or naproxen suspension and other treatment options before deciding to use naproxen, ec-naproxen, naproxen sodium or naproxen sodium ds. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation ). naproxen as naproxen, ec-naproxen, naproxen sodium or naproxen sodium ds is indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen as naproxen, naproxen sodium and naproxen sodium ds is also indicated: - for relief of the

Estados Unidos - inglés - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr), clidinium bromide (unii: 91zqw5jf1z) (clidinium - unii:bo76jf850n) - chlordiazepoxide hydrochloride 5 mg - chlordiazepoxide hcl/clidinium bromide is indicated to control emotional and somatic factors in gastrointestinal disorders. chlordiazepoxide hcl/clidinium bromide may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. chlordiazepoxide hcl/clidinium bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. it is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. the more severe withdrawal symptoms have usually been limited to tho

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - sevelamer carbonate - film-coated tablet - 800 milligram(s) - drugs for treatment of hyperkalemia and hyperphosphatemia; sevelamer